Genetic Testing Gaps Testing for hereditary mutations is increasingly recommended for people with cancer, but recommendations do not always translate into access to testing and appropriate counseling. by Kate Yandell Survivor Profile Sharing Her Strength Diagnosed with two cancers prior to turning 40, Rebecca Esparza uses her voice to advocate for policy changes to help people affected by cancer. by Lindsey Konkel Medicare Coverage for Next-Generation Sequencing Tests Multigene panels that rely on next-generation sequencing are increasingly used to test for hereditary cancer risk-related mutations. The federal government aims to expand Medicare coverage for these tests. by Ashley P. Taylor BRCA: Who Should Be Tested? Genetic testing for mutations in the BRCA1 and BRCA2 genes creates opportunities for cancer risk reduction. But 25 years after the mutations were discovered, some who could benefit from testing are still left out. by Sue Rochman Our Own Words People with cancer and their loved ones find ways for their voices to be heard without filters. by Bradley Jones Finding Support in Unlikely Places After her diagnosis with ovarian cancer, Patricia Anne Ward noticed that some friends and family pulled away. She found connection outside her usual circles. by Patricia Anne Ward Advocacy Spotlight: Sorting Out Priorities Ovarian cancer survivor and research advocate Annie Ellis is teaming up with researchers to better equip patients with recurrent cancer to make treatment decisions. by Cici Zhang Forward Look Little Consensus on Ovarian Cancer Monitoring Tests and scans may be overused. by Kate Yandell Survivor Profile Going Full Bore Susan Leighton, a 19-year survivor, is a powerful advocate for ovarian cancer research. Her advocacy, which began locally in northern Alabama, has reached the National Cancer Institute and the Department of Defense. by Sue Rochman Forward Look Identifying Ovarian Cancer Risk Study may help spotlight women who would benefit from risk reduction strategies. by Carrie Printz next Cancer Talk Drug Delays Recurrence in People With Early-Stage Breast Cancer People who have inherited BRCA mutations and are at high risk for cancer recurrence may benefit from a PARP inhibitor. by Pamela Rafalow Grossman Open Medical Records: Pros and Cons Patients now have full access to their online medical records. What are the benefits and downsides? by Jen Tota McGivney Remote Care After adapting remote patient monitoring programs to cancer patients with COVID-19, cancer centers delve deeper into the programs’ value for cancer patients undergoing treatment. by Jon Kelvey Moving Away From the Maximum Tolerated Dose The FDA recently expressed a new commitment to testing cancer drugs at lower doses, rather than defaulting to the highest dose most people can tolerate. by Marcus A. Banks More Posts